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Abstract 
Background: Altered gut microbiota is implicated in cow’s milk allergy (CMA) and differs markedly from healthy, 
breastfed infants. Infants who suffer from severe CMA often rely on cow’s milk protein avoidance and, when breast‑
feeding is not possible, on specialised infant formulas such as amino‑acid based formulas (AAF). Herein, we report the 
effects of an AAF including specific synbiotics on oral and gastrointestinal microbiota of infants with non‑IgE medi‑
ated CMA with reference to healthy, breastfed infants.
Methods: In this prospective, randomized, double‑blind controlled study, infants with suspected non‑IgE mediated 
CMA received test or control formula. Test formula was AAF with synbiotics (prebiotic fructo‑oligosaccharides and 
probiotic Bifidobacterium breve M‑16V). Control formula was AAF without synbiotics. Healthy, breastfed infants were 
used as a separate reference group (HBR). Bacterial compositions of faecal and salivary samples were analysed by 16S 
rRNA‑gene sequencing. Faecal analysis was complemented with the analysis of pH, short‑chain fatty acids (SCFAs) 
and lactic acids.
Results: The trial included 35 test subjects, 36 controls, and 51 HBR. The 16S rRNA‑gene sequencing revealed moder‑
ate effects of test formula on oral microbiota. In contrast, the gut microbiota was substantially affected across time 
comparing test with control. In both groups bacterial diversity increased over time but was characterised by a more 
gradual increment in test compared to control. Compositionally this reflected an enhancement of Bifidobacterium 
spp. and Veillonella sp. in the test group. In contrast, the control‑fed infants showed increased abundance of adult‑like 
species, mainly within the Lachnospiraceae family, as well as within the Ruminococcus and Alistipes genus. The effects 
on Bifidobacterium spp. and Lachnospiraceae spp. were previously confirmed through enumeration by fluorescent 
in situ hybridization and were shown for test to approximate the proportions observed in the HBR. Additionally, 
microbial activity was affected as evidenced by an increase of l‑lactate, a decrease of valerate, and reduced concentra‑
tions of branched‑chain SCFAs in test versus control.
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Background
The prevalence of food allergy in infancy and childhood 
is increasing in many countries worldwide. Cow’s milk 
allergy (CMA) is among the most common food aller-
gies in early life and is associated with growth retardation 
throughout childhood, particularly in children suffering 
from persistent milk allergy [1]. Comorbidity is common, 
and many children develop other allergic conditions 
over time, also referred to as the allergic March [2]. The 
microbes that colonize the mucosal tissues after birth 
have a pivotal role in both innate and adaptive immune 
development [3, 4] and may have long-term effects both 
on the susceptibility and the persistence of allergic dis-
ease [5, 6].
Breastfeeding provides the infant gastrointestinal tract 
with a plethora of bioactive factors and has profound 
effects on gut microbiota composition and functions 
[7–9] and, as more recently reported, on oral microbiota 
development [10, 11]. Infants who suffer from severe 
CMA rely on cow’s milk protein avoidance and, when 
breastfeeding is not possible, require specialised infant 
formulas such as extensively hydrolysed formula (eHF) or 
amino acid-based formula (AAF) [12]. Incorporation of 
prebiotics, probiotics, or their combination (synbiotics) 
in these formulas offers a safe, suitable and effective strat-
egy for both the dietary management and for potentially 
optimizing microbiota development in both IgE- and 
non-IgE-mediated CMA infants [13, 14].
In a randomized controlled trial with non-IgE-medi-
ated CMA infants (ASSIGN study), an improvement 
of gut microbiota was observed in infants receiving an 
AAF with specific synbiotics (test) compared to infants 
receiving the same AAF without synbiotics (control). 
This improvement was based on an enhancement of bifi-
dobacteria and a decrease of the Eubacterium rectale/
Clostridium coccoides (ER/CC) group; in both test levels 
were close to the levels observed for a separate healthy, 
breastfed reference (HBR) group after an 8-week inter-
vention [15]. Recently, it was reported that the levels of 
both microbial groups were sustained for the full study 
period of 26 weeks [16]. The fluorescence in situ hybridi-
zation (FISH) method used is an effective approach to 
quantify specific bacterial groups, but it does not provide 
information on the full bacterial composition and diver-
sity of the community. For this, application of next-gen-
eration sequencing technologies are typically needed [17, 
18]. We hypothesized that synbiotics would have a more 
comprehensive effect on the microbiota composition and 
activity. Therefore, we performed an in-depth characteri-
sation of the microbial compositions of both faecal and 
saliva specimens collected in the ASSIGN study through 
16S ribosomal RNA (16S rRNA)-gene sequencing, and 
in addition investigated the effects on gut physiology 
and bacterial metabolic activity by analysis of faecal pH, 
short-chain fatty acids (SCFA) and lactate.
Methods
Study design
ASSIGN was a prospective, randomized, double-blind 
controlled study (Netherlands Trial Register NTR3979) 
including infants with suspected non-IgE mediated CMA 
and a separate non-randomized healthy, breastfed refer-
ence group (HBR). Detailed methods on how the trial 
was conducted, and the primary and secondary outcome 
measures, have been published previously [15, 16].
In brief, subjects < 13  months of age with non-IgE 
mediated CMA were stratified based on predominant, 
investigator-assessed symptoms (skin or gastrointestinal) 
and randomly allocated to receive test (n = 35) or con-
trol formula (n = 36). Study duration was 26 weeks with 
allocation to study product for at least 8  weeks. After 
8 weeks, randomized subjects continued to use the allo-
cated study product or switched to commercially avail-
able eHF, or other milk substitute as per clinical practice 
guidelines of each medical centre. Subjects in the HBR 
group were age-matched to week 8 of the randomized 
groups (n = 51). Infants in the test group received an 
AAF (Neocate LCP; Nutricia Advanced Medical Nutri-
tion, Liverpool, UK) including a prebiotic blend of chic-
ory-derived neutral oligofructose and long-chain inulin 
(BENEO-Orafti SA, Oreye, Belgium) (9:1 ratio at a total 
concentration of 0.63  g/100  ml) and a probiotic strain 
Bifidobacterium breve M-16V (Morinaga Milk, Tokyo, 
Japan) at a concentration of 1.47 × 109 colony-forming 
units (CFU)/100  ml formula. The control formula was 
a commercially available AAF (Neocate LCP; Nutricia 
Advanced Medical Nutrition, Liverpool, UK).
Collection of saliva and stool samples
Saliva samples were collected from randomized infants 
at baseline and 8  weeks by a healthcare professional 
using the SalivaBio Children’s Swab method (Salimetrics, 
Conclusions: The AAF including specific synbiotics effectively modulates the gut microbiota and its metabolic activ‑
ity in non‑IgE mediated CMA infants bringing it close to a healthy breastfed profile.
Trial registration Registered on 1 May 2013 with Netherlands Trial Register Number NTR3979.
Keywords: Cow’s milk allergy, Pediatrics, Gut microbiota, Prebiotics, Probiotics
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Carlsbad, USA) at least 1 h after feeding. Stool samples 
from randomized infants were collected, as reported pre-
viously [15], by parents/guardians at baseline, 8, 12 and 
26  weeks. Parents/guardians of the age-matched non-
randomized infants in the HBR group were asked to 
collect stool samples only. Saliva and stool specimens col-
lected in the clinic were immediately frozen at − 80  °C. 
Stool specimens collected at home were immediately fro-
zen in home-freezers and transported with ice-packs to 
the clinic by parents/guardians or by courier for storage 
at − 80 °C. Thereafter, both saliva and stools were trans-
ported on dry-ice (solid  CO2) to Nutricia Research and 
stored at − 80 °C until analysis.
DNA extraction
DNA extraction from saliva samples was performed with 
DNeasy Blood and Tissue Kits (Qiagen, Venlo, the Neth-
erlands) according to the manufacturer’s protocol, except 
for an adaptation in the enzymatic lysis step and the addi-
tion of a mechanical lysis step as pre-treatment before 
the DNA isolation procedure. In brief, 150  µl of saliva 
sample was diluted up to 350 µl in PBS buffer (150 mM 
NaCl, 10 mM Na2HPO4, 20 mM NaH2PO4, pH 7.4) to 
which 50 µl of lytic enzymatic cocktail was added (50 mg/
ml lysozyme, Sigma-Aldrich, St. Louis, Missouri, United 
States, USA and 20  µl proteinase K from Qiagen kit) 
and 300 mg of 0.1 mm glass beads (Biospec, Bartlesville, 
Oklahoma, USA). This suspension was incubated at 37 °C 
for 30  min, followed by one round of bead-beating for 
10 min at 25 Hz (Tissuelyser I, Qiagen, Venlo, the Neth-
erlands) and followed by the QIAcube isolation proce-
dure (Qiagen).
DNA extraction from stools samples was performed 
with QIAmp DNA Stool Mini Kit (Qiagen, Venlo, the 
Netherlands) according to the manufacturer’s proto-
col except for the addition of two bead-beating steps as 
described before [19]. Extracted DNA from stools were 
purified from extraction impurities using spin columns 
(DCC™, Zymo research, Irvine, California, USA).
Microbiota profiling
Faecal and salivary microbiota compositions were pro-
filed by sequencing the hypervariable V3–V4 regions 
of the 16S rRNA gene. Sequencing was performed by 
LifeSequencing S.L. (Valencia, Spain) on an Illumina 
MiSeq instrument (San Diego, California, USA). The 
V3–V4 region was PCR-amplified with universal prim-
ers S-D-Bact-0341-b-S-17 primer (forward 5′-CCT 
ACG GGNGGC WGC AG-3′) and S-D-Bact-0785-a-
A-21 primer (reverse 5′-GAC TAC HVGGG TAT CTA 
ATC C-3′) [20] designed for dual indexing following the 
Illumina 16S Metagenomic Sequencing Library Prepa-
ration protocol (Part # 15044223 Rev. B). In brief, PCR 
amplification was performed in two steps: (1) in a first 
step, the V3–V4 region was amplified with the addition 
of universal adaptors to the amplification products. All 
amplicons were purified (AMPure XP, Beckman, Dan-
vers, MA) to remove short amplification products and 
quantified using the Quant-iT PicoGreen dsDNA kit 
(Invitrogen, Carlsbad, California, USA). (2) In the second 
PCR step, the amplicons from the first step were ampli-
fied by targeting the universal adapters and with the addi-
tion of sample specific indexes and sequencing adaptors. 
The final amplicons were purified (AMPure XP) and 
quantified using the Quant-iT PicoGreen ds DNA kit 
(Invitrogen). All samples were pooled in equal amounts 
and sequenced in a 300 bp paired-end mode.
Bioinformatic analysis of sequence data
Illumina reads were trimmed (removal of primers) 
and quality filtered by removing all reads with a mean 
q-score lower than 20 with ‘cutadapt v1.4.1’ [21]. Paired-
end reads were merged using the program ‘PEAR v0.9.6’ 
[22]. Merged reads with q > 15 over a window of 5 bases, 
no ambiguous bases and a minimal length of 300 were 
retained and analysed with the ‘Quantitative Insights 
Into Microbial Ecology’ (QIIME) v1.9.0 package [23]. 
Sequences were clustered into operational taxonomic 
units (OTUs) based on 97% sequence identity as proxy 
for bacterial species using VSEARCH v2.03 with exclu-
sion of chimeric sequences identified against the RDP 
gold database [24, 25]. Taxonomic assignment was 
performed using the RDP classifier [26] against the 
SILVA119 database [27]. Singleton OTUs, and OTUs 
with eukaryotic assignments, as well as OTUs with a low 
relative abundance (counts of an OTU as proportion of 
total reads of a sample) up to 0.005% were excluded from 
further downstream analysis. Representative sequences 
of OTUs were aligned using PyNAST [28] and used to 
build a phylogenetic tree with FastTree [29]. Rarefaction 
of the OTU tables was applied to account for the differ-
ences in sequencing depths (number of reads per sam-
ple) between the samples with default settings (10 equal 
depths from 10 sequences/sample up to the median 
number of sequences/sample with 10 iterations at each 
sequencing depth). The tree and rarefied OTU tables 
were used to calculate the species diversity (α-diversity) 
of the samples using Faith’s phylogenetic diversity (PD) 
[30] and the Shannon index for diversity [31].
The sequences within an OTU of interest (i.e. identified 
as differentially abundant from the statistical compari-
sons performed) were further partitioned into homog-
enous nodes with high sequence identity using the MED 
v2.1 algorithm [32]. Taxonomic assignment of the MED 
nodes were performed using the RDP classifier [26] 
against the SILVA119 database [27]. The assignment of 
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the node with the largest number of reads and highest 
sequence identity was subsequently used as a more accu-
rate proxy to the taxonomy of that OTU.
Additional faecal sample parameters
To assess overall bacterial metabolic activity, the follow-
ing faecal sample parameters were measured as described 
previously [33]: pH, concentrations of short-chain fatty 
acids (SCFAs) (i.e. acetate, propionate, butyrate, isobu-
tyrate, valerate, and isovalerate), and d- and l-lactate.
FISH was applied to quantify the Bifidobacterium 
genus and Eubacterium rectale/Clostridium coccoides 
group (ER/CC) as described previously [18] using 
the 16S rRNA-targeted oligonucleotide probes S-G-
Bif-0164  m-a-A-18 (5′-CAT CCG GYA TTA CCA CCC -3′) 
[34, 35] and S-*-Erec-0482-a-A-19 (5′-GCT TCT TAG 
TCA RGT ACC G-3′) [17], respectively.
Data handling and statistical analyses
All analyses were performed on intention-to-treat data 
set (ITT), defined as all randomized subjects. Overall, the 
statistical analyses were performed comparing test with 
the control group per specimen analysed (saliva or fae-
cal). The HBR group data was used as reference only and 
not as an intervention group. Statistical analyses were 
performed by using  SAS® (SAS Enterprise Guide version 
4.3 or higher) for Windows (SAS Institute Inc., Cary, NC) 
unless indicated otherwise. Results are expressed and 
presented as mean values and standard deviations unless 
stated otherwise.
16S rRNA‑gene sequencing data
The species diversity (α-diversity) indexes calculated 
in QIIME from the 16S rRNA-gene sequencing data 
were analysed at one single rarefied sequencing depth. 
The sequence depth which was selected for comparison 
was based on the maximum rarefaction depth where all 
or most of the samples were still included. Differences 
between treatment groups across time were tested using 
a random intercept mixed model including baseline in 
the outcome vector, adjustment for stratification factor 
(skin or gastrointestinal symptoms), treatment, time and 
treatment by time interaction as fixed factors. For assess-
ing the treatment effect over time, significance of the 
treatment by time interaction was used.
The non-rarefied OTU tables obtained from QIIME 
were trimmed, removing sparse OTUs with at most 10 
non-zero observations. Statistical analysis of the bacte-
rial compositions was performed by applying a combi-
nation of multivariate analysis with Canoco 5 software 
[36], followed by differential abundance testing using 
the two-part statistics method [37]. Firstly, the con-
strained ordination method, known as redundancy 
analysis (RDA), was used to test time-dependent treat-
ment effects with adjustment for stratification factor. 
The Monte Carlo permutation test (MCPT) with 1000 
permutations was used to evaluate statistically signifi-
cant differences (P ≤ 0.05) of the resulting model. If found 
significant, the top-15 responding OTUs identified from 
the RDA model were subsequently tested for differential 
abundance at the different timepoints using the two-part 
statistics method [37]. If the two-part statistics method 
could not be applied due to a small number of non-zero 
observations, then only presence-absence was considered 
by applying the Chi square test (if ≥ 5, but < 10 non-zeros 
in both groups) or Barnard test (if < 5 non-zeros in one 
group). The Benjamini–Hochberg false-discovery rate 
(FDR) was used to correct for multiple comparisons in 
the differential abundance tests [38] and significance was 
considered when FDR ≤ 0.1 at week 8 or when FDR ≤ 0.1 
for at least two visits (i.e. 12 and 26 weeks).
Other faecal parameters (pH, FISH outcomes, SCFAs, lactic 
acids)
The following rule was applied to faecal parameters that 
were subject to limit of detection (LOD): If a value was 
below detection limit and the percentage of values below 
detection limit was at most 30%, then the value was 
replaced with LOD/2. For parameters with more than 
30% of the values below LOD only presence-absence 
was considered, and P-values were based on a logistic 
regression model. The P-values for continuous data were 
based on the analysis of covariance (ANCOVA) or Van 
Elteren test depending on normality of the residuals. All 
statistical models were corrected for baseline levels (if 
applicable) and stratification factor, and for statistical sig-
nificance P ≤ 0.05 was considered.
Results
Subject characteristics were well balanced between 
groups as reported previously [15]. In total, 378 
(125 saliva and 253 faecal) samples were successfully 
sequenced with a sequencing depth ranging from 15,265 
to 129,780, and a median depth of 39,761 sequences per 
sample (Table  1). Principal component analysis (PCA), 
which is an unconstrained ordination method [36], was 
used to explore the taxonomic compositions of saliva 
and faecal samples. A clear clustering by sample origin 
was observed (Fig.  1a), which confirms that community 
composition is primarily determined by body habitat 
[39]. A summary of the most dominant taxa identified at 
the bacterial family level showed that saliva compared to 
faecal samples were typically characterized by increased 
relative abundance of Streptococcaceae (53.3 ± 17.8%), 
Microcrococcaceae (9.7 ± 6.4%) and Actinomycetaceae 
(5.2 ± 5.8%). Faecal samples were typically characterized 
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Table 1 Summary of saliva and faecal samples of subjects with CMA (ITT) and the healthy reference group (age-matched 
to week 8)
Sequence depth, after filtering for low quality reads, is given as mean (± SD)
Saliva samples Faecal samples Grand total
Test (N = 35) Control (N = 36) Test (N = 35) Control (N = 36) Healthy subjects (N = 51)
Week 0
 n subjects 35 (100%) 36 (100%) 29 (83%) 33 (92%)
 Mean (SD) 30,258 (14,753) 28,802 (6845) 47,476 (14,165) 47,269 (22,263)
Week 8
 n subjects 24 (69%) 30 (83%) 24 (69%) 31 (86%) 48 (94%)
 Mean (SD) 27,387 (6555) 29,724 (15,773) 47,037 (13,765) 47,909 (16,532) 51,871 (19,134)
Week 12
 n subjects 18 (51%) 26 (72%)
 Mean (SD) 52,921 (13,491) 51,391 (19,953)
Week 26
 n subjects 21 (60%) 23 (64%)
 Mean (SD) 51,706 (22,464) 55,888 (17,966)
Grand total Saliva samples Faecal samples All samples
 n samples 125 253 378
 Mean (SD) 29,160 (11,837) 50,200 (18,201) 43,242 (19,124)
Fig. 1 Principal component analysis (PCA) of faecal and salivary microbiota composition (a) and summary of major bacterial families identified (b). 
The PCA sample scatterplot is displayed on the first two axes summarizing most of the species variation, which is based on the OTU count data for 
each sample. The distance between the sample symbols (rounds for saliva and squares for faecal) approximates the dissimilarity of their species 
composition as measured by their Euclidean distance. Mean relative abundances (± SD) are summarized at the family level (“_f_”) for taxa > 1% and 
summarized in the heat map (red–yellow–green color scheme indicating high to low relative abundance). Abbreviations used for bacterial phylum 
levels: Acti actinobacteria, Bact bacteroidetes, Firm firmicutes, Prot proteobacteria, Verr verrucomicrobia
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by Bacteroidaceae (20.9 ± 18.7%), Lachnospiraceae 
(15.4 ± 12.8%), Enterobacteriaceae (14.2 ± 14.2%), Bifido-
bacteriaceae (7.6 ± 9.2%), Ruminococcaceae (6.7 ± 8.2%) 
and Verrucomicrobiaceae (5.3 ± 10.7%) (Fig. 1b).
Bacterial diversity
The species diversity indexes (PD and Shannon) were 
analysed at a rarefaction depth of 16,114 sequences per 
sample, which omitted one saliva sample (control, week 
8) from comparison. Control and test group did not dif-
fer in salivary species diversity based on PD (Fig. 2a) or 
Shannon index (Fig. 2c). A treatment effect over time was 
observed for faecal species diversity, which was charac-
terized by a more gradual increment (from baseline until 
26w) in test compared to control for both PD (Fig.  2b, 
estimated difference per week = − 0.022, P = 0.069) 
and Shannon index (Fig.  2d, estimated difference per 
week = − 0.026, P = 0.005). The estimated average dif-
ference between test versus control was significantly 
different at week 12 (PD = − 0.349, P = 0.031 and Shan-
non = − 0.236, P = 0.049) and week 26 (PD = − 0.653, 
P = 0.012 and Shannon = − 0.596, P = 0.002). The 
HBR group showed the lowest average diversity 
(PD = 4.37 ± 1.14 and Shannon = 3.63 ± 0.80) compared 
to both test (PD = 4.89 ± 1.05 and Shannon = 3.75 ± 0.67) 
and control (PD = 5.17 ± 0.88 and Shannon = 4.01 ± 0.71) 
at week 8.
Time‑dependent treatment effects on oral microbiota
Redundancy analyses (RDA) were carried out to test the 
effect of treatment (test/control) across time on the sali-
vary community composition. We fitted both an RDA 
with and without correction for timepoint (baseline and 
week 8) and compared the results of the MCPT on the 
first axis of the model. The P value for the RDA with cor-
rection for timepoint (0.3816) was larger than our pre-set 
threshold of 0.05, so we used the simpler model (with 
P = 0.003) as a basis for interpreting the time-depend-
ent treatment effects. The top 15 OTUs with the best fit 
on the first two axes (explaining most of the variation) 
were plotted in the RDA (Fig. 3a) and further evaluated 
for differential abundances between test and control 
using the two-part statistics method [37]. No differences 
were observed at baseline (based on FDR ≤ 0.1), but two 
OTUs out of this top 15 were found differentially abun-
dant between test and control at week 8. This included 
a decreased relative abundance of Peptostreptococcus 
sp. (Fig. 3b, FDR = 0.0525) and an increased presence of 
Parabacteroides sp. (Fig. 3c, FDR = 0.0525).
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Fig. 2 Plots summarizing the bacterial diversity of saliva (a, c) and faecal samples (b, d) using Faith’s phylogenetic diversity and the Shannon index, 
respectively. The symbols and error bars show the least square (LS) means with 95% CI for treatment by time. The faecal bacterial diversity of the 
HBR reference group (age‑matched to week 8) is plotted as well. P‑values are based on a random intercept mixed model with week 8/12/26 values 
as outcome, stratification factor and baseline values as covariate and treatment as fixed effect: *P ≤ 0.05 and **P ≤ 0.01
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Time‑dependent treatment effects on gut microbiota
In order to assess the time-dependent treatment effects 
for the faecal community composition we used the Prin-
cipal Response Curves (PRC) method [40]. The PRC is 
based on the RDA method, in which the principal com-
ponent is plotted against time (baseline, week 8, 12 and 
26) to enable the assessment and visualization of time-
dependent treatment effects. The MCPT applied to test 
the significance of the resulting PRC model was signifi-
cant for the first axis (P = 0.001). The top 15 OTUs with 
the best fit on the first axis were plotted (Fig. 4a) and fur-
ther evaluated with the two-part statistics method [37]. 
No differences were observed at baseline, but a total of 
13 OTUs out of the top 15 were confirmed to be dif-
ferentially abundant between test and control at week 
8 or at 2 or more timepoints. This included increased 
relative abundances in test versus control of 6 OTUs, 
of which 5 were assigned to Bifidobacterium and 1 was 
assigned to the Veillonella genus. The other 7 OTUs 
showed decreased relative abundances, of which 5 were 
assigned to 3 genera within the Lachnospiraceae fam-
ily (Tyzzerella, Blautia and Lachnoclostridium) and 2 
were assigned to the genera Ruminococcus and Alistipes, 
respectively.
FISH quantification of faecal bacterial groups
The treatment effects on gut microbiota, as revealed by 
16S rRNA-gene sequencing, were mostly associated with 
a relative increase of several species of the genus Bifido-
bacterium and a decrease of several species of the family 
Lachnospiraceae. FISH enumeration of these two bacte-
rial groups was used to verify the absolute differences 
in abundance between treatments, of which results have 
been reported before [15, 16]. In summary, FISH analy-
sis confirmed a significant enrichment of bifidobacteria 
in test versus control across time (Fig. 4b). Moreover, the 
proportions for test (36.0 ± 22.4%) as compared to that 
of the control group at week 8 (14.5 ± 16.4%) were close 
to the levels observed for the HBR group (48.1 ± 26.5%). 
The FISH probe used to quantify the ER/CC group tar-
gets the majority of Lachnospiraceae spp. including the 
differentially abundant OTUs associated with the genera 
Tyzzerella, Blautia and Lachnoclostridium as identified 
with 16S rRNA-gene sequencing. A decreased abundance 
Fig. 3 Redundancy analysis (RDA) biplot showing the change in species composition from week 0 to week 8 in saliva samples of infants receiving 
test or control formula (a). The top 15 OTUs are plotted based on best fit with the first two RDA axes. In bold the OTUs that were significantly 
different at week 8 between test versus control as confirmed with the two‑part statistics method. The proportion of zeros (plotted as bars) and the 
median of the non‑zero values (plotted as points) are displayed for the two differentially abundant OTU’s assigned to Peptostreptococcus (b) and 
Parabacteroides (c), respectively. False discovery rate (FDR) was used to correct the raw P‑values for multiple testing with significance at 0.1. bOnly 
the Barnard test was performed (if < 5 non‑zeros in one group) to compare the proportion of zeros. The OTU‘s are summarized with unique (but 
arbitrary) numbers as identifiers, and genus level (“_g_”) and phylum level taxonomic assignments: Acti actinobacteria, Bact bacteroidetes, Firm 
firmicutes, Fuso fusobacteria, Prot proteobacteria, Sacc saccharibacteria
Page 8 of 13Wopereis et al. Clin Transl Allergy            (2019) 9:27 
of the ER/CC group in test versus control across time 
confirm these findings (Fig.  4c). Additionally, the levels 
for test (11.8 ± 10.9%) as compared to that of the control 
group at week 8 (25.2 ± 16.9%) were close to the levels 
observed for the HBR group (10.4 ± 10.6%).
Faecal pH, SCFA and lactate
To assess whether the observed changes in gut micro-
biota composition also led to changes in gut physiology 
and microbial metabolites produced, the faecal pH and 
levels of SCFA and lactate were determined. No statisti-
cally significant differences were observed for faecal pH, 
acetate, propionate, butyrate, iso-valerate (Fig. 5a–e) and 
d-lactate (Fig.  5i) at the different timepoints. l-lactate 
was detected in a greater number of samples in test ver-
sus control at week 26 (38 vs. 4%, P = 0.020) (Fig.  5h). 
In contrast, valerate was detected in a smaller number 
of samples in test versus control at week 8 (44 vs. 12%, 
P = 0.036) and week 26 (67 vs. 29%, P = 0.021) (Fig. 5g). 
Moreover, the concentration of iso-butyrate was lower in 
test versus control at 26 weeks (P = 0.050) (Fig. 5f ).
Correlations of faecal microbiota composition 
and metabolic activity across time
A redundancy analysis was used to summarize the fae-
cal microbiota composition over time as explained by 
treatment (Test or Control) and the HBR group (Fig. 6a). 
The RDA recapitulates the results of the PRC analysis, 
but in addition confirmed the proximity in community 
composition of the test group at week 8 with the HBR. 
The additional faecal parameters measured (FISH, pH, 
SCFAs and lactic acids) were supplemented to this RDA 
in a separate biplot (Fig. 6b). An inverse correlation was 
observed for the FISH quantified levels of Bifidobac-
terium spp. with the ER/CC group, which reflects the 
major differences observed for test (and HBR) with the 
control group. Moreover, the increase of Bifidobacterium 
spp. in test was positively correlated with increased levels 
of l-lactate. In contrast, the more abundant levels of the 
Fig. 4 Principal response curves (PRC) of faecal microbiota composition showing the change in species composition of infants receiving test 
formula as compared to control (a). The diagram shows the first component of the PRC on the vertical axis and time on the horizontal axis with the 
treatments plotted as single response curves using control as reference with zero PRC values and so its curve lays over the horizontal axis. The top 
15 OTUs are plotted on the separate vertical (one‑dimensional) plot based on best fit with the first component of the PRC. In bold the OTUs that 
were significantly increased (> 0) or decreased (< 0) in Test versus Control at week 8 or at two or more timepoints (week 8/12/26) as confirmed by 
the two‑part statistics (FDR ≤ 0.1). Percentages (means with 95% CI) of bifidobacteria (b), and ER/CC group (c) quantified by FISH at week 0/8/12/26. 
The HBR reference values (age‑matched to week 8) are plotted as well. P‑values are based on ANCOVA comparing Test versus Control with Week 
8/12/26 values as outcome, stratification factor and baseline values as covariate and treatment as fixed effect: **P ≤ 0.01; ***P ≤ 0.001. Taxa names 
are given at the OTU level with unique (but arbitrary) numbers as identifiers, genus level (“_g_”), family level (“_f_”): Bact bacteroidaceae, Bifi 
bifidobacteriaceae, Lach lachnospiraceae, Rumi ruminococcaceae, Veil veillonellaceae; and phylum level: Acti actinobacteria, Bact bacteroidetes, Firm 
firmicutes
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ER/CC group across time in control was associated with 
increased levels of butyrate, valerate, iso-butyrate and 
iso-valerate. In test, the ER/CC group gradually increased 
from 12 to 26 weeks, which was associated (similarly as 
for control) with an increment of butyrate, valerate, iso-
butyrate and iso-valerate at 26 weeks.
Discussion
We previously reported the specific enhancement of 
bifidobacteria and decrement of the ER/CC group in 
the faeces of infants receiving the AAF with synbiot-
ics consisting of a prebiotic blend of oligofructose and 
long-chain inulin and the probiotic strain Bifidobacte-
rium breve M-16V [15, 16]. In this study, we applied a 
16S rRNA-gene sequencing approach on both faecal and 
saliva specimens to elucidate more specifically which 
taxa responded to the intervention within the respective 
bacterial communities and what the effect was on their 
diversity and functionality.
We demonstrated that the effect of the synbiotic-con-
taining AAF on infant microbiota was most pronounced 
for the gastro-intestinal tract and only minimally affected 
the oral microbiota. The AAF including synbiotics com-
pared to the AAF without synbiotics showed a more 
gradual increment over time of bacterial diversity, which 
is also typically observed in longitudinal studies investi-
gating early life gut microbiota development of breast-
fed infants as compared to formula-fed infants [7, 8, 41, 
42]. These studies showed that the lower diversity of 
gut microbiota in breastfed infants is not only observed 
0
1
2
3
4
5
iso-butyric acid
m
m
ol
/k
g
w
et
w
ei
gh
tf
ae
ce
s
w0 w8 w12 w26
0
2
4
6
8
iso-valeric acid
m
m
ol
/k
g
w
et
w
ei
gh
tf
ae
ce
s
w0 w8 w12 w26
w0 w8 w12 w26
5.0
5.5
6.0
6.5
7.0
pH
st
oo
lp
H
Control
Test
HBR
0
50
100
150
200
acetate
m
m
ol
/k
g
w
et
w
ei
gh
tf
ae
ce
s
w0 w8 w12 w26
Control
Test
HBR
0
20
40
60
propionic acid
m
m
ol
/k
g
w
et
w
ei
gh
tf
ae
ce
s
w0 w8 w12 w26
0
20
40
60
butyric acid
m
m
ol
/k
g
w
et
w
ei
gh
tf
ae
ce
s
w0 w8 w12 w26
w0 w8 w12 w26
0
20
40
60
80
valeric acid
%
 d
et
ec
te
d
w0 w8 w12 w26
0
20
40
60
80
L-lactic acid
%
 d
et
ec
te
d
w0 w8 w12 w26
0
20
40
60
D-lactic acid
%
de
te
ct
ed
p=0.090 p=0.062
p=0.098
p=0.062 *
*
*
*
a b c
d e f
g h i
Fig. 5 Mean with 95% CI of stool pH (a) for treatment by time. The box‑plots summarize the amounts (in mmol/kg) of acetate (b), propionate (c), 
butyrate (d), iso‑valerate (e), iso‑butyrate (f) for treatment by time, respectively. Percentage of faecal samples (plotted as bars) with detectable levels 
of valerate (g), l‑lactate (h), and d‑lactate (i) for treatment by time, respectively. The HBR reference values (age‑matched to week 8) are plotted as 
well. P‑values for stool pH and acetate are based on ANCOVA comparing Test versus Control with week 8/12/26 values as outcome, stratification 
factor and baseline values as covariate and treatment as fixed effect. P‑values for the variables summarized in c–e are based on Van Elteren test 
comparing test versus control with respect to change from baseline at week 8/12/26, taken the stratification factor into account. P‑values for the 
variables summarized in g–i are obtained from a logistic regression model comparing test versus control at week 8/12/26 with adjustment for 
baseline values. *P ≤ 0.05
Page 10 of 13Wopereis et al. Clin Transl Allergy            (2019) 9:27 
during the exclusive human milk-feeding period, but also 
during the complementary feeding-period until full tran-
sition to family foods, which reflects the sustained effects 
of human milk oligosaccharides on the bifidobacterial 
species that effectively thrive on these compounds [7, 
8]. The AAF including synbiotics was found to enhance 
the bifidobacterial community, as several bifidobacte-
rial species had increased, which was also reflected by 
an increase of the fermentation end-product l-lactate 
in the faeces of these infants. Interestingly, the concord-
ant increase observed in this study for Veillonella sp. is 
most likely explained by the ability of this species to uti-
lize and convert lactate into propionate [43]. In contrast, 
the infants receiving the control formula showed an early 
adoption of adult-like bacterial taxa belonging to the ER/
CC group (resembling Lachnospiraceae spp.), namely 
Tyzzerella, Blautia and Lachnoclostridium spp., as well 
as species of Ruminococcus and Alistipes. This increase of 
adult-like taxa was associated with an increase of valer-
ate and the branched-chain SCFA iso-butyrate, which are 
fermentation products that result from the degradation 
of proteins and amino acids [44, 45]. Overall, these results 
indicate that the synbiotic-supplemented AAF induced a 
saccharolytic fermentation profile, while infants receiving 
the AAF without synbiotics showed a more proteolytic 
fermentation activity, which is generally associated with 
metabolite profiles that may be less beneficial for colonic 
health [46, 47].
To date, several case–control studies have specifically 
investigated the gastrointestinal microbiota of infants 
and children with confirmed CMA compared to age-
matched healthy controls [48–52]. All of them reported 
altered gut microbiota in infants and children with 
CMA, although with mixed findings. However, the com-
mon characteristics that were identified in these stud-
ies included lower levels of bifidobacteria [49–52] and 
increased levels of members of the heterogenous ER/CC 
group [48–50]. In analogy with our study, the case–con-
trol study of Thompson-Chagoyan et al. [48] in addition 
observed increased fecal butyrate and branched-chain 
SCFA (iso-butyrate, iso-valerate) concentrations in CMA 
infants compared to healthy infants. Interestingly, our 
study demonstrated that 8-weeks use of the synbiotic-
supplemented AAF approximated the composition and 
activity of the gut microbiota of the age-matched healthy, 
breastfed reference group.
Our study has several limitations as addressed before 
[15], which includes the challenges in making and con-
firming a specific and accurate diagnosis of non-IgE 
mediated allergy. The chance of including infants with 
Fig. 6 RDA plot of faecal microbiota composition based on treatment by time interaction and the HBR reference group (age‑matched to week 8) as 
explanatory variables (a). OTUs that were identified as differentially abundant between test and control are plotted as biplot arrows in the RDA plot 
on the left. The same RDA plot is shown on the right (b), but then supplemented with faecal pH, FISH counts and levels of SCFA and lactic acids as 
correlation biplot. Variables that were significantly different between test and control are shown in bold. Taxa names are given at the OTU level with 
unique (but arbitrary) numbers as identifiers and the family level (“_f_”): Bact bacteroidaceae, Bifi bifidobacteriaceae, Lach lachnospiraceae, Rumi 
ruminococcaceae, Veil veillonellaceae
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other (food) allergy presentations were mitigated by 
applying a robust diagnostic work-up [15]. For a num-
ber of subjects, no specimens were available due to 
insufficient material or not completing the study until 
26 weeks (Table 1), which limited the number of evalu-
able samples at week 12 and 26. This limitation was 
however similar in test and control groups and would, 
therefore, not have affected the observed differences 
between groups. Moreover, the identified microbial 
signatures showed very consistent patterns across 
time and were, regarding the relative abundances of 
bifidobacteria and the ER/CC group, independently 
confirmed by 16S rRNA-gene sequencing and FISH. 
Although, we specifically studied subjects with non-
IgE-mediated CMA, Burks et  al. [14] showed that an 
AAF, including ingredients from the current synbiotic 
blend, was safe in patients with IgE and non-IgE-medi-
ated CMA, and affected the microbial signatures in an 
equal manner. Importantly, this study was primarily 
designed to investigate the effects of the synbiotic-con-
taining AAF on gut microbiota and the suitability for 
the use in dietary management of CMA. As reported 
previously [14–16], the AAF including synbiotics 
showed reduction of allergic symptoms as seen for the 
control AAF, and in addition showed potential benefi-
cial systemic effects based on the adverse events, which 
reported fewer subjects in test with infections and 
need for anti-infective medication, including antibiot-
ics [14–16] and lower use of agents for dermatological 
purposes [16]. Currently investigations are ongoing to 
assess whether the AAF including synbiotics influences 
cow’s milk tolerance acquisition in a clinical trial con-
ducted in infants with confirmed IgE-mediated CMA 
(Netherlands Trial Register NTR3725).
Conclusions
Based on the data showing pronounced effects on gut 
microbiota composition, diversity and metabolic activity, 
we conclude that the AAF including the specific synbiot-
ics offers an effective nutritional strategy to modulate the 
gut microbiota of infants with suspected non-IgE-medi-
ated CMA closer to a healthy breastfed profile.
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